

DO NOT ENTER
FN.
6/3/04

In the claims:

1-112. (Cancelled)

113. (Currently amended) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising:

contacting a multi-epitopic antigen present in a host's serum with a composition comprising a binding agent that specifically binds to a first epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen pair, whereby an effective host T cell response is elicited against a ~~second epitope on the antigen in-on~~ the binding agent/antigen pair.

114-116. (Cancelled)

117. (Currently amended) The method of claim 113, further comprising a humoral immune response against a second epitope on the antigen.

118. (Previously presented) The method of claim 113, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

119. (Previously presented) The method of claim 118, wherein the soluble antigen is a soluble tumor-associated antigen.

120. (Previously presented) The method of claim 118, wherein the soluble antigen is associated with a human cancer.

121-122. (Cancelled)

123. (Previously presented) The method of claim 113, wherein the binding agent is an antibody or a polypeptide including an antigen binding portion thereof.